1. Considered and approved Audited Financial Results for the Quarter and Financial Year ended 31st March, 2026 along with the along with the Auditors Report thereon, Statement of Assets ....

Profit growth above 25%Exceptional itemDebt to equity above the thresholdResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.8%Reaction day

₹139.00

prior close

₹139.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.7%-3.6% vs market

Healthcare Service Provider peers, median of 24sector-1.2%-1.6% vs sector

On the reaction day the stock moved 3.6 pts less than Nifty Microcap 250 and 1.6 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+2.2

10m

+0.7

15m

+0.7

30m

+0.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.8+0.7-3.6-1.2-1.6

Next day

-3.8+0.7-4.5+1.3-5.0

-8.6+0.0-8.7+1.2-9.8

-13.2-1.1-12.1-1.3-11.9

-12.2+0.0-12.2-0.8-11.4

-12.2+0.3-12.5-0.8-11.4

-11.5+1.1-12.6-0.6-10.9

15d

-10.1+4.9-14.9+1.6-11.7

-15.1+5.3-20.4-0.1-15.0

-18.0+6.9-24.9-4.1-13.9

+8.5+11.9-3.4+0.8+7.6

UpDownMarket · Nifty Microcap 250Sector · Healthcare Service Provider peers, median of 24Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Choksi Laboratories reported full-year FY2026 revenue of ₹4,621.93 Lakhs, up 10.1% from ₹4,178.23 Lakhs in FY2025. PAT grew 29% to ₹196.43 Lakhs (vs ₹152.33 Lakhs prior year). Q4 standalone revenue was ₹1,282.22 Lakhs with PAT of ₹102.68 Lakhs. An exceptional item of ₹75.30 Lakhs was recorded from the sale of an office flat (non-recurring). The company maintained an unqualified audit opinion with no qualifications or going concern issues. Total debt increased to ₹3,017.82 Lakhs vs equity of ₹2,557.54 Lakhs (D/E ratio 1.18). Cash flow from operations declined to ₹786.48 Lakhs from ₹1,177.80 Lakhs in the prior year. The company operates in analytical testing and calibration services.

Likely market impact

Revenue growth of 10% is modest; PAT growth of 29% is strong, boosted by a one-time exceptional item. Rising debt levels and declining operating cash flow are concerns. The clean audit opinion provides comfort to investors.